The Germinal Center/Activated B-Cell Subclassification Has a Prognostic Impact for Response to Salvage Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Bio-CORAL Study | Zendy

Catherine Thiéblemont | Zendy; Josette Brière | Zendy; Nicolas Mounier | Zendy; Hans-Ullrich Voelker | Zendy; Wendy Cuccuini | Zendy; Edouard Hirchaud | Zendy; Andreas Rosenwald | Zendy; Andrew Jack | Zendy; Christer Sundström | Zendy; Sergio Cogliatti | Zendy; Philippe Trougouboff | Zendy; L Boudová | Zendy; Loïc Ysebaert | Zendy; Jean Soulier | Zendy; Catherine Chevalier | Zendy; Dominique Bron | Zendy; Norbert Schmitz | Zendy; Philippe Gaulard | Zendy; Rémi Houlgatte | Zendy; Christian Gisselbrecht | Zendy

Open Access

The Germinal Center/Activated B-Cell Subclassification Has a Prognostic Impact for Response to Salvage Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Bio-CORAL Study

Author(s) -

Catherine Thiéblemont,

Josette Brière,

Nicolas Mounier,

Hans-Ullrich Voelker,

Wendy Cuccuini,

Edouard Hirchaud,

Andreas Rosenwald,

Andrew Jack,

Christer Sundström,

Sergio Cogliatti,

Philippe Trougouboff,

L Boudová,

Loïc Ysebaert,

Jean Soulier,

Catherine Chevalier,

Dominique Bron,

Norbert Schmitz,

Philippe Gaulard,

Rémi Houlgatte,

Christian Gisselbrecht

Publication year - 2011

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2011.35.4423

Subject(s) - medicine , rituximab , international prognostic index , diffuse large b cell lymphoma , oncology , salvage therapy , bcl6 , autologous stem cell transplantation , progression free survival , lymphoma , germinal center , chemotherapy , b cell , immunology , antibody

To evaluate the prognostic value of the cell of origin (COO) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBLC), prospectively treated by rituximab, dexamethasone, high-dose cytarabine, and cisplatin (R-DHAP) versus rituximab, ifosfamide, carboplatin, and etoposide and followed by intensive therapy plus autologous stem-cell transplantation on the Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL) trial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research